HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study
- 17 October 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 18 (4), 698-710
- https://doi.org/10.1007/s10120-014-0432-5
Abstract
We used real-time quantitative polymerase chain reaction (rqPCR) to detect human epidermal growth factor receptor 2 (HER2) amplification in the circulating cell-free DNA (cfDNA) of patients with gastric cancer (GC), which shows the spatial and temporal intrinsic heterogeneity of HER2 expression/copy number during progression, for liquid biopsy and treatment monitoring. We first enrolled 52 patients with advanced GC who underwent surgery and 40 healthy volunteers. For patients with GC, plasma cfDNA was obtained before surgery (43 patients) and during postoperative treatment (nine of 43 patients). After ribonuclease P RNA component H1 (RPPH1) had been selected as a reference gene for HER2 CN assessment by rqPCR in GC tumours and plasma, plasma HER2-to-RPPH1 ratios were determined retrospectively in a development cohort and an additional independent validation cohort. The HER2-to-RPPH1 ratio of GC tissues determined by rqPCR was concordant with routinely determined HER2 status. The plasma HER2-to-RPPH1 ratio was significantly higher for patients with HER2-positive tumours than for those with HER2-negative tumours. The sensitivity and specificity of the plasma HER2-to-RPPH1 ratio test were 0.539 and 0.967, respectively, in the development cohort, and 0.667 and 1.000, respectively, in the validation cohort. HER2 amplifications acquired and lost during tumour progression and treatment, respectively, were apparently detected by repeated assessments of plasma HER2-to-RPPH1 ratios during postoperative treatment. Our preliminary data demonstrated the potential clinical use of circulating cfDNA to detect HER2 amplification as a therapeutic marker to detect and monitor HER2 CN status for effective molecular targeted therapy in patients with GC.Keywords
This publication has 29 references indexed in Scilit:
- Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With TrastuzumabJournal of Clinical Oncology, 2013
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancerEuropean Journal of Cancer, 2013
- Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome SequencingScience Translational Medicine, 2012
- Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancerInternational Journal of Clinical Oncology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 TestingJournal of Clinical Oncology, 2008
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008
- Understanding diagnostic tests 3: receiver operating characteristic curvesActa Paediatrica, 2007
- Screening of DNA copy‐number aberrations in gastric cancer cell lines by array‐based comparative genomic hybridizationCancer Science, 2005